Pliant Therapeutics
PLRX
143 hedge funds and large institutions have $1.5B invested in Pliant Therapeutics in 2023 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 57 increasing their positions, 30 reducing their positions, and 23 closing their positions.
90% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 30
83% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 23
74% more capital invested
Capital invested by funds: $861M → $1.5B (+$634M)
23% more call options, than puts
Call options by funds: $11.8M | Put options by funds: $9.61M
14% more funds holding
Funds holding: 125 → 143 (+18)
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
3.73% more ownership
Funds ownership: 91.68% → 95.41% (+3.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$50.2M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$48.1M |
| 3 |
FAM
Fred Alger Management
New York
|
+$30.1M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$28.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$25.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$27.1M |
| 2 |
Jennison Associates
New York
|
-$14.4M |
| 3 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
-$8.01M |
| 4 |
CA
CHI Advisors
New York
|
-$4.78M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$3.35M |
PLRX Hedge Fund Activity: Q1 2023 in Review
143 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q1 2023, worth a combined $1.5B — up 74% from $861M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new PLRX positions and 23 closed out — a net gain of 19 holders — while 57 added to existing stakes and 30 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $50.2M. The largest seller was Redmile Group, cutting an estimated $27.1M.
- 143 institutional investors held Pliant Therapeutics (PLRX) as of Q1 2023, up from 125 in Q4 2022.
- Funds reported $1.5B of Pliant Therapeutics stock for Q1 2023, up 74% quarter-over-quarter.
- 42 funds opened new Pliant Therapeutics positions in Q1 2023 and 23 closed out, a net change of +19 holders.
- The largest Pliant Therapeutics buyer in Q1 2023 was RA Capital Management, an estimated $50.2M added.
- The largest Pliant Therapeutics seller in Q1 2023 was Redmile Group, an estimated $27.1M sold.
Based on aggregated 13F filings for Q1 2023.